A World Health Organization-led programme to ensure poorer countries get fair access to Covid-19 vaccines, tests and treatments aims to secure antiviral drugs for patients with mild symptoms for as little as US$10 per course, a draft document seen by Reuters says.

Merck & Co's experimental pill molnupiravir is likely to be one of the drugs, and other drugs to treat mild patients are being developed.